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https://doi.org/10.1016/j.celrep.2021.109662SUMMARYImmune cells are armed with Toll-like receptors (TLRs) for sensing and responding to pathogens and other
danger cues. The role of extracellular-signal-regulated kinases 1/2 (Erk1/2) in TLR signaling remains enigmatic,
with both pro- and anti-inflammatory functions described.We reveal here that the immune-specific transmem-
brane adaptor SCIMP is a direct scaffold for Erk1/2 in TLR pathways, with high-resolution, live-cell imaging
revealing that SCIMP guides the spatial and temporal recruitment of Erk2 tomembrane ruffles andmacropino-
somes for pro-inflammatory TLR4 signaling. SCIMP-deficient mice display defects in Erk1/2 recruitment to
TLR4, c-Fos activation, and pro-inflammatory cytokine production, with these effects being phenocopied by
Erk1/2 signaling inhibition. Our findings thus delineate a selective role for SCIMP as a key scaffold for themem-
brane recruitment of Erk1/2 kinase to initiate TLR-mediated pro-inflammatory responses in macrophages.INTRODUCTION
Immune cells propagate signals from specific receptors through
the recruitment of a diverse suite of cytoplasmic signaling mole-
cules to specific membrane domains. Toll-like receptors (TLRs)
are a well-studied family of immune receptors that detect path-
ogen or damage-associated signatures to elicit programs of
pro- and anti-inflammatory cytokines and other innate immune
responses (Akira and Takeda, 2004; Medzhitov, 2001). TLRs
on the plasma membrane, endosomes, or macropinosomes
are paired with specific sets of signaling adaptors (MyD88,
Mal, TRIF, and TRAM), which trigger cascades of signaling ki-
nases, including mitogen-activated protein kinases (MAPKs),
to activate inflammatory transcription factors, such as nuclear
factor kB (NF-kB), activator protein 1 (AP-1), CCAAT/enhancer
binding protein b (C/EBPb), and interferon regulatory factors
(IRFs) (Kawai and Akira, 2007; Lu et al., 2009; Schmitz et al.,
2007; Smolinska et al., 2011). These activated transcription fac-
tors then drive specific inflammatory cytokine production (Luo
et al., 2019; O’Neill and Bowie, 2007).
The MAPK extracellular-signal-regulated kinase 1/2 (Erk1/2)
plays a key role in TLR-mediated inflammatory pathways, stim-
ulating both pro- and anti-inflammatory cytokine production as
well as regulating expression of TLRs themselves in responseC
This is an open access article under the CC BY-Nto activation (An et al., 2002; Dumitru et al., 2000; Eliopoulos
et al., 2003). In many other cell types and receptor-signaling
pathways, Erk1/2 is recruited to activated receptors, such as re-
ceptor tyrosine kinases (RTKs) and G protein coupled receptors
(GPCRs) by scaffold proteins, including IQ-motif containing Ras
GTPase-activating-like proteins (IQGAPs), p21-activated kinase
1 (PAK1), caveolae-associated protein 4 (CAVIN4), paxillin, and b
arrestins, which help to confine Erk1/2 activation and signaling to
specific receptor-associated locales and pathways within cells
(Casar and Crespo, 2016; Lavoie et al., 2020; Ogata et al.,
2014). Activation of Erk1/2 during TLR-mediated inflammatory
responses involves kinase signaling cascades, including the
TPL2/MEK/Erk module (Banerjee et al., 2006; Kuriakose et al.,
2014). However, these upstream elements do not provide a
mechanism for spatiotemporal recruitment of Erk1/2 to activated
TLRs in order to direct distinct pro- or anti-inflammatory immune
signaling.
SLP adaptor and C-terminal Src kinase (CSK)-interacting
membrane protein (SCIMP) is an immune-specific, transmem-
brane-signaling adaptor and a member of the palmitoylated
transmembrane adaptor protein (pTRAP) family (Curson et al.,
2018; Stepanek et al., 2014). It drives Erk1/2 signaling down-
stream of major histocompatibility complex type II (MHC II) and
dectin-1 receptors in B cells and dendritic cells (DCs) (Draberell Reports 36, 109662, September 7, 2021 ª 2021 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. SCIMP is internalized on macropinosomes in response to LPS
Live imaging of CRISPR-Cas9-mediated SCIMP knockout RAW264.7 cells expressing Halo-SCIMP (red) incubated with 488-Dextran-70k (green) prior to im-
aging. Time series of cells stimulated with 100 ng/mL LPS for 30 min (A) shows SCIMP localized to cell surface ruffles (arrows) and internalized dextran-positive
macropinosomes (arrowheads). Standardized intensity profiles of Halo-SCIMP and 488-Dextran across themacropinosome (dashed line) quantified for individual
channels are shown. Unstimulated cells are shown in (B). All images are from a single experiment. Scale bar: 10 mm (inset scale bar: 5 mm).
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OPEN ACCESSet al., 2011; Kralova et al., 2016). In macrophages, SCIMP is a
TLR-interacting protein that promotes receptor phosphorylation
and transient MAPK signaling responses, including Erk1/2 (Luo
et al., 2017). Phosphorylated SCIMP functions as a signaling
adaptor and membrane scaffold for an array of effectors,
including Src kinases. SCIMP paired with TLR4 or other cell-sur-
face and intracellular TLRs acts to initiate a notably selective pro-
gram of pro-inflammatory cytokines (Luo et al., 2017, 2020), and
most recently, SCIMP has been implicated in inflammasome-
driven interleukin-1b (IL-1b) production (Zewinger et al., 2020).
Indeed, SCIMP is increasingly associated with autoimmune
and pro-inflammatory-driven diseases (Dozmorov et al., 2014;
Jansen et al., 2019).
In this study, we employ binding partner screens and high-res-
olution, live-cell imaging to reveal that Erk1/2 is recruited by
SCIMP to dynamic membrane domains in response to TLR4
stimulation. Using signaling and cytokine assays, we describe
a key signaling and transcriptional mechanism downstream of
TLR4 and SCIMP for Erk1/2-mediated c-Fos and NF-kB activa-
tion and pro-inflammatory cytokine expression. Our results2 Cell Reports 36, 109662, September 7, 2021reveal SCIMP as an important transmembrane TLR adaptor for
scaffolding Erk1/2 at specific membrane signaling domains in
macrophages, providing a mechanism for spatiotemporally re-
cruiting Erk1/2 to TLRs for pro-inflammatory responses.
RESULTS
SCIMP is positioned at TLR4 signaling sites on ruffles
and macropinosomes
As a transmembrane TLR adaptor and pTRAP, SCIMP is clus-
tered in tetraspanin-enriched microdomains (TEMs) and deter-
gent-resistant lipid membrane domains along with receptors, in-
tegrins, and tetraspanins (Horejsı́ et al., 2004;Cursonet al., 2018).
We and others have shown that TLR signaling adaptors and ki-
nases are clustered on cell-surface ruffles and the macropino-
somes arising from them in activated macrophages (Kagan
et al., 2008; Luo et al., 2014a). Staining of SCIMPon fixed cells re-
vealed that it localizes to cell surface protrusions, including filo-
podia anddorsal ruffles (Figure S1A; Luo et al., 2017). To examine
SCIMPbehavior in live cells,weperformed live-cell imaging using
Figure 2. Erk1/2 interacts with SCIMP
(A) GST-SCIMP-T1 coupled to GSH-Sepharose was used for pull-downs from LPS-activated (100 ng/mL) RAW 264.7 cell extracts. Bound proteins were
separated by SDS-PAGE and visualized using colloidal Coomassie staining for gel excision. Excised bands were identified by liquid chromatography-mass
spectrometry or mass spectrometry. A major band at ~42 kDa, absent from the GST control, was identified as Erk2.
(B) The sequence coverage of identified peptides in Erk2. Mass spectrometry analysis identified six independent trypsin-digested peptides from Erk2with at least
98% confidence, including one peptide not found in Erk1. The predicted molecular mass of each peptide approximately matches with experimental molecular
mass.
(C) Identified SCIMP binding partners. The mass spectrometry score is a measurement of peptide confidence from the ProteinPilot scoring algorithm: Score =
log(1  (percent confidence/100)). %Cov (coverage) refers to the percentage of all identified peptide(s) relative to total amino acid sequence, whereas %Cov
(50%) and %Cov (95%) refer to peptide coverage with 50% and 95% confidence, respectively. All peptides are identified from a single experiment.
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OPEN ACCESSSCIMP CRISPR-deleted RAW264.7 macrophages stably recon-
stituting exofacially-taggedHalo-SCIMP. In both LPS-stimulated
(Figure 1A) and unstimulated cells (Figure 1B), Halo-SCIMP was
localized on the cell surface, where it was enriched on filopodia
and ruffles, and it was also present on vacuolar compartments in-
side cells. The addition of the fluid-phase marker 488-dextran
70 kDa, a specific marker for macropinosomes (Commisso
et al., 2014), to themediumduring imaging confirmed that SCIMP
is on the membranes of large dextran-filled vacuolar macropino-
somes that internalize from ruffles in response to LPS treatment
(Figure 1A; Video S1). Imaging of unstimulated cells showed
that SCIMP was predominantly localized to the cell surface and
was also present on some smaller, constitutive, dextran-positive
macropinosomes, indicating a lower level of SCIMP internaliza-
tion under basal conditions. Its enrichment on ruffles andmacro-
pinosomes therefore positions SCIMP to participate in TLR
signaling, and as a transmembrane adaptor, it is poised to recruit
signaling molecules at these sites.
Erk1/2 is recruited to SCIMP downstream of TLR4
SCIMP scaffolds the Src kinase Lyn to recruit multiple effectors
Grb2, Csk, and B-cell linker protein (BLNK)/SLP65, which bind tospecific TLR-inducible phosphorylated tyrosine sites in the
SCIMP cytoplasmic tail. SCIMP also potentiatesMAPK signaling
and the rapid activation of Erk1/2 downstream of TLR activation
in macrophages (Luo et al., 2017, 2020; Figures S1B and S1C).
As SCIMP itself does not possess intrinsic kinase activity, we hy-
pothesized that SCIMP interactors must control downstream
Erk1/2 signaling. To comprehensively identify additional SCIMP
interactors and interrogate a possible relationship between
SCIMP and Erk1/2, we performed an unbiased screen using a
glutathione S-transferase (GST)-SCIMP cytoplasmic tail
construct (T1) to pull-down binding partners from LPS-treated
macrophage extracts (Figure 2A). Mass spectrometry analysis
of pull-downs showed that, in addition to known SCIMP binding
partners, including TLR4, Lyn, and Grb2, Erk2 itself is an unex-
pected SCIMP interactor based on its identification by six inde-
pendent trypsin-digested peptides, each with over 95% confi-
dence (Figures 2B and 2C).
The recruitment of Erk2 by SCIMP was then verified using af-
finity pull-downs and immunoprecipitations from RAW264.7
macrophage extracts (Figure 3). For affinity pull-downs, we
used two truncated forms of the SCIMP cytoplasmic tail pro-
duced as GST fusion proteins: GST-SCIMP T1 comprising theCell Reports 36, 109662, September 7, 2021 3
Figure 3. LPS promotes Erk1/2 recruitment to SCIMP
(A) SCIMP cytoplasmic domain constructs T1 (amino acids C29–F150) and truncation T2 (amino acids S93–F150). Created with BioRender.com.
(B) Bacterially expressed GST-SCIMP-T1 and GST-SCIMP-T2 were used to pull down Erk1/2 and other known binding partners (TLR4, Lyn, and Grb2) from LPS-
stimulated (100 ng/mL) RAW264.7 cell lysates.
(C) CRISPR-Cas9-mediated SCIMP knockout RAW264.7 cells stably expressing V5-taggedWT SCIMPwere treated ± 100 ng/mL LPS for 30min, after which cell
lysates were prepared, SCIMP-V5 was immunoprecipitated, and immunoblotting for Erk1/2 and TLR4 was performed.
(legend continued on next page)






OPEN ACCESSentire intracellular region and GST-SCIMP T2 comprising the
C-terminal region (Figure 3A). Both GST-SCIMP T1 and T2
were able to bind to Erk1/2 from LPS-activated macrophage ex-
tracts with statistical analyses showing no difference in Erk1/2
binding between T1 and T2 (Figure 3B). In contrast, endogenous
TLR4 was pulled down by SCIMP-T1 more efficiently than
SCIMP-T2, as previously reported (Luo et al., 2017). In addition,
Grb2 and Lyn, which bind to phosphorylated Y58 and the pro-
line-rich domain (PRD) of SCIMP, respectively, were selectively
pulled down by only SCIMP-T1 as expected. This indicates
that the C terminus of SCIMP, rather than Y58 or the PRD, is
the primary binding site for Erk1/2 recruitment.
Next, CRISPR-mediated, SCIMP-deficient RAW264.7 cells re-
constituted with recombinant V5-tagged SCIMP (Luo et al.,
2017) were used to examine Erk1/2 binding in cells. Immunopre-
cipitation of SCIMP-V5 showed co-immunoprecipitation of Erk1/
2 in addition to the known binding partner, TLR4 (Luo et al.,
2017), with SCIMP/TLR4/Erk complex formation enhanced by
LPS treatment (Figure 3C). SCIMP is rapidly phosphorylated by
Lyn at Y58, Y96, and Y120 upon LPS stimulation (Luo et al.,
2017). To examine whether any of these tyrosine residues regu-
late Erk1/2 binding, we used GST-tagged, site-specific phos-
phorylation-deficient SCIMP mutants (Y58F, Y96F, and Y120F).
Affinity pull-downs with each of these mutants revealed no
change in the binding of Erk1/2, suggesting that SCIMP phos-
phorylation at these three sites is not required for Erk1/2 recruit-
ment in extracts from LPS-activated macrophages (Figure 3D).
As controls for binding specificity, Lyn binding (at the PRD
domain) was not affected by any of the tyrosine mutants,
whereas Grb2, Csk, and SLP65 binding was reduced in Y58F-,
Y96F-, or Y120F-expressing cells, respectively (Luo et al.,
2017). Together, these results show that Erk1/2 is bound to the
C-terminal tail of SCIMP, and this binding is enhanced in LPS-
treated cells, but it does not involve LPS-induced phosphory-
lated tyrosines or indeed effectors recruited to these sites.
Unlike other TLRs, TLR4 signaling is mediated through all of
the classical TLR adaptorsMyD88,MAL, TRIF, and TRAM,which
are required for downstream TPL2/MEK/Erk1/2 signaling (Bane-
rjee et al., 2006; O’Neill and Bowie, 2007). Using a GST-SCIMP-
T1 pull-down in Mal-, Trif-, or Trif/Tram-deficient immortalized
mouse bone marrow-derived macrophages (iBMMs), we tested
the requirement for these adaptors in the recruitment of Erk1/2
by SCIMP. As expected, SCIMP constitutively binds to Lyn,
and this was unaffected in adaptor-deficient iBMMs. Notably,
Mal was found to be required for the pull-down of Erk1/2 by
SCIMP, although the absence of either Trif or Tram did not affect
SCIMP-Erk binding (Figure 3E, upper). All adaptor-deficient cells
showed a reduction in LPS-induced Erk1/2 phosphorylation in
whole-cell lysates compared to wild-type (WT) cells (Figure 3E,(D) Representative immunoblot showing pull-down of GST-SCIMP-T1 WT, Y58F,
Lyn, Grb2, Csk, and SLP65.
(E) Representative immunoblot showing pull-down of GST-SCIMP-T1 in 100 ng/m
Erk1/2, phospho-Erk1/2 (Thr-202/Tyr-204), Lyn, and GAPDH (input samples).
(F) GST-SCIMP-T1 was used to pull down Erk1/2 from 100 ng/mL LPS-stimulat
(U0126) for 1 h. Immunoblots were probed for Erk1/2, phospho-Erk1/2 (Thr-202/
Graphical data in (B), (D), and (E) (upper graph) show relative Erk1/2 levels normal
cell lysates (lower graph) as mean+SEM from 3 independent experiments (n = 3
multiple comparisons test (B) or Student’s t test (D and E) (ns, non-significant; *plower), as has been previously reported (Horng et al., 2002;
Choi et al., 2010), indicating that activation of Erk1/2 itself is
not required for its recruitment by SCIMP. This was confirmed
by treatment with the MEK1/2 inhibitor U0126, which showed
that SCIMP-Erk1/2 binding was unaffected by inhibition of
Erk1/2 phosphorylation (Figure 3F). Therefore, Mal may act to
bridge Erk1/2 recruitment to SCIMP, prior to its promotion of
Erk1/2 activation in response to TLR4 stimulation.
SCIMP recruits Erk1/2 to membrane ruffles and
macropinosomes
Erk1/2 is scaffolded by other proteins on specific membrane
compartments in a variety of receptor-signaling pathways,
including epidermal growth factor receptor (EGFR) signaling
(Lavoie et al., 2020). In macrophages, Erk1/2 is generally a solu-
ble kinase present throughout the cytoplasm, yet TLR signaling
occurs on specific domains of the plasma membrane and mac-
ropinosomes and endosomes. As we showed that SCIMP is
positioned at the TLR signaling sites on ruffles and macropino-
somes and given its ability to bind to Erk2, we hypothesized
that SCIMP may scaffold Erk2 at these sites for immune
signaling. RAW264.7 macrophages co-expressing Halo-SCIMP
andGFP-Erk2 were used for live imaging, which showed that, af-
ter addition of LPS, Erk2 can be recruited to membrane ruffles
where SCIMP resides (Figure 4A). In line with its role in EGFR
signaling, GFP-Erk2 also showed enrichment on membrane ruf-
fles following epidermal growth factor (EGF) stimulation; how-
ever, Halo-SCIMP did not strongly localize to these sites, indi-
cating that EGF-mediated membrane recruitment of Erk2
occurs independently of SCIMP. Ruffles and macropinosomes
are highly dynamic membranes, and to characterize the spatio-
temporal recruitment of Erk2 and SCIMP for TLR4 signaling, we
performed high-speed, high-resolution, live-cell imaging of co-
transfected, LPS-stimulated macrophages using lattice light-
sheet microscopy (LLSM) (Condon et al., 2018). The resulting
movies capture active ruffles that are enriched for both Halo-
SCIMP and GFP-Erk2, giving rise to large, spherical macropino-
somes, which were internalized (over 1 min) with both SCIMP
and Erk2 remaining attached to the limiting membrane of the
newly closed macropinosome (Figure 4B; Video S2). A 2D slice
depicts SCIMP-Erk2 colocalization on the dorsal ruffles and on
internalized macropinosomes (Figure 4C; Video S3). The degree
of colocalization in these regions was visualized as a ratiometric
composite shown as a heatmap depicting intense convergence
of Erk2 and SCIMP on the ruffles and newly formed macropino-
somes, compared to ‘‘cooler’’ regions of the plasma membrane
and other cellular compartments (Figures 4B and 4C; Videos S2,
S3, and S4). This also highlights the acute, transient nature of
Erk2 recruitment at these sites in response to LPS; cells withoutY96F, and Y120F in LPS-stimulated RAW264.7 cell lysates probed for Erk1/2,
L LPS-stimulated WT, Mal/, Trif/, and Trif//Tram/ iBMMs probed for
ed RAW264.7 cell lysates pre-treated with DMSO or 10 mM MEK1/2 inhibitor
Tyr-204), and GAPDH.
ized to bait or phospho-Erk1/2 normalized to GAPDH loading control in whole-
), and statistical analysis was performed using one-way ANOVA with Sidak’s
< 0.05; **p < 0.01; ****p < 0.0001).
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Figure 4. Erk1/2 and SCIMP colocalize on ruffles and macropinosomes in response to LPS
(A) CRISPR-Cas9-mediated SCIMP knockout RAW264.7 cells expressing Halo-SCIMP (red) and GFP-Erk2 (green) with or without stimulation with 100 ng/mL
LPS or 100 ng/mL EGF for 30 min. Scale bar: 50 mm (inset scale bar: 10 mm).
(legend continued on next page)






OPEN ACCESSLPS stimulation showed reduced membrane colocalization of
Erk2 and SCIMP (Video S5). These images demonstrate the co-
localization of SCIMP and Erk2 on membrane domains, in keep-
ing with their LPS-induced molecular interactions.
To determine whether SCIMP is required for the recruitment of
Erk1/2 at membrane signaling sites, SCIMP-deleted RAW264.7
macrophages expressing GFP-Erk2 were imaged. These cells
showed no enrichment of Erk2 at cell-surface ruffles induced
by LPS stimulation; however, Erk2 recruitment to ruffles was
then rescued by re-expression of Halo-SCIMP (Figure 5A). Affin-
ity pull-down using the GST-tagged Toll/interleukin-1 receptor
(TIR) domain of TLR4 in LPS-stimulated WT and Scimp/
bone marrow-derived macrophages (BMMs) showed that the
recruitment of Erk1/2 to TLR4 was significantly diminished in
the absence of SCIMP (Figure 5B). Furthermore, immunoprecip-
itation of Erk1/2 from WT and Scimp/ BMMs showed binding
of TLR4 and Erk1/2 in WT BMMs, which was enhanced by LPS
stimulation; however, no Erk1/2-TLR4 binding was detected in
Scimp/ BMMs, indicating that SCIMP is needed to scaffold
Erk1/2 to activated TLR4 (Figure 5C). Together, these results
pinpoint the cellular location of the SCIMP-Erk2 complex to sites
on macrophage ruffles and macropinosomes, in response to
TLR4 activation, and position SCIMP as a critical spatiotemporal
scaffold for LPS-induced recruitment of Erk1/2 to these key TLR
signaling sites.
SCIMP and Erk1/2 signaling for selective TLR-mediated
cytokine production
The TPL2/Erk1/2 axis is known to promote both pro- and anti-in-
flammatory cytokine production downstream of activated TLRs,
reflecting a broad role in cytokine programming for both the pro-
motion and resolution of TLR-mediated inflammation (Banerjee
et al., 2006). Erk1/2 regulates pro-inflammatory cytokines,
including tumor necrosis factor (TNF), IL-6, and IL-1b (Flynn
et al., 2019; Rousseau et al., 2008; Singh et al., 2016), as well
as anti-inflammatory IL-10 (Sanin et al., 2015). Accordingly,
BMMs treated withMEK1/2 inhibitor, U0126, showed decreased
expression of these cytokines compared to untreated BMMs in
response to LPS stimulation (Figure S2).
Although Erk1/2 signaling has a broad cytokine profile, SCIMP
is selective in promoting a biased output of TLR-mediated pro-
inflammatory cytokines IL-6 and IL-12p40 in macrophages, but
not anti-inflammatory IL-10 or interferon b (IFNb) (Luo et al.,
2017). Given the recruitment and activation of Erk1/2 by SCIMP,
we examined the production of Erk1/2-dependent cytokines in
SCIMP-deficient BMMs activated with LPS. BMMs from both
SCIMP homozygous (Scimp/) and heterozygous (Scimp+/)
knockout mice were deficient in the synthesis of TNF, IL-6, and
IL-12p40, and of IL-1b, but not IL-10, compared to WT controls
(Scimp+/+) (Figure 6A). Scimp+/ BMMs expressed around 30%
of the WT level of SCIMP, and yet the magnitude of the cytokine(B) Time series of 100 ng/mL LPS-treated RAW264.7 cell expressing Halo-SCIM
SCIMP and GFP-Erk2 computated from a sum intensity projection (SIP) using Im
endosomes (arrowheads) are indicated. Scale bar: 50 mm (inset scale bar: 10 mm
(C) x,z 2D reslice of a single frame from cell from (B) captured using LLSM. Coloc
and visualized using FireLUT is shown. Cell surface ruffles (arrowheads) and end
Images from (A)–(C) are from independent experiments.defects was similar to those seen in Scimp/ BMMs, suggest-
ing that even a partial reduction in SCIMP expression impairs
LPS-induced pro-inflammatory cytokine production. Consis-
tently, Scimp/ BMMs showed decreased secretion of TNF,
IL-6, and IL-12p40 protein over a time course of 8 h and 24 h
LPS treatment, and IL-10 secretion was unaffected by loss of
SCIMP (Figure 6B). These findings were replicated after SCIMP
silencing, where, in addition to IL-6 and IL-12p40 (Figure S3A),
Scimp small interfering RNA (siRNA)-treated BMMs showed a
reduction in LPS-induced IL-1b and TNF expression (Figure 6C).
In addition to IL-10 and IFN-b, SCIMP silencing did not affect the
expression of inflammatory chemokines CXCL10, CCL2, and
CCL5 in response to LPS (Figure S3A). SCIMP deficiency there-
fore results in a specific defect in the pro-inflammatory arm of
Erk1/2-mediated cytokine production downstream of TLR4
activation.
In promoting these selective effects on TLR-mediated cytokine
production, it is important tonote that expressionofSCIMP itself is
considerably upregulated by LPS activation (Figure S3B).
Because SCIMP has close homologs within the pTRAP family,
we examined the expression of Phosphoprotein associated with
glycosphingolipid-enriched microdomains (PAG)/Csk-binding
protein (CBP), Non-T cell activation linker (NTAL), and Linker for
activation of T cells (LAT) in SCIMP-silenced BMMs, finding that
all were unaffected by the loss of SCIMP (Figure S3C). BMMs
frommice deficient in the closely related but non-myeloid specific
pTRAP, PAG/CBP (Cbp/), were stimulated with LPS, and the
expression of pro-inflammatory cytokines TNF, IL-1b, and IL-
12p40 was unaffected by loss of PAG/CBP, which was itself ex-
pressed at very low levels in BMMs (Figure S3D). Thus, SCIMP
hasaspecific role in scaffoldingErk1/2,which results in a selective
effect on LPS-induced pro-inflammatory cytokine expression. To
further explore a mechanism for this selective induction down-
stream of TLRs, Erk1/2- and SCIMP-mediated transcriptional
regulation was next explored.
Transcriptional regulation of cytokines through the
SCIMP-Erk1/2 axis
TLR-induced cytokine production is transcriptionally regulated
through the activity of inflammatory transcription factors, which
directly activate or suppress target gene expression. Erk1/2
plays a role in NF-kB activation (Banerjee et al., 2006), and it
phosphorylates AP-1 component c-Fos in TLR pathways (Brown
et al., 2011; Chalmers et al., 2007; Gilley et al., 2009). BMMs
treated with the upstream MEK1/2 inhibitor U0126 to abolish
Erk1/2 signaling showed a significant dose-dependent reduction
in c-Fos phosphorylation after LPS stimulation but showed no
detectable change in NF-kB p65 phosphorylation compared to
controls (Figure S4A). NF-kB phosphorylation promotes its
pro-inflammatory transcriptional activity (Sasaki et al., 2005),
and MAPK-mediated phosphorylation of AP-1 componentsP (red) and GFP-Erk2 (green) captured using LLSM. Colocalization of Halo-
ageJ and visualized using FireLUT is shown. Cell surface ruffles (arrows) and
).
alization of Halo-SCIMP (green) and GFP-Erk2 (red) computated using ImageJ
osomes (arrows) are indicated. Scale bar: 10 mm (inset scale bar: 5 mm).
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Figure 5. SCIMP is required for LPS-induced
Erk1/2 localization at cell-surface ruffles and
recruitment to TLR4
(A) Representative images of untreated and
100 ng/mL LPS-stimulated CRISPR-Cas9-medi-
ated SCIMP knockout RAW264.7 cells expressing
GFP-Erk2 (green) alone or in combination with Halo-
SCIMP (red) and stained with phalloidin-647 (white).
Z projections across the membrane (dashed white
line) show dorsal surface ruffles after LPS treatment
(arrowheads). Intensity profiles of ruffles quantified
for individual channels are shown (yellow dashed
line). Scale bar: 50 mm.
(B) Bacterially expressed GST-TLR4-TIR was used
to pull down Erk1/2 from 100 ng/mL LPS-stimulated
Scimp+/+ and Scimp/ BMM cell lysates and
probed for Erk1/2, SCIMP, and GAPDH (input
samples).
(C) Erk1/2 was immunoprecipitated from untreated
and 30 min LPS-treated (100 ng/mL) WT and
Scimp/BMMs, and immunoblots were probed for
TLR4, Erk1/2, SCIMP, and GAPDH. Anti-human
immunoglobulin G (IgG) was used as a negative
immunoprecipitation control.
(B) and (C) are each representative of two inde-
pendent experiments (n = 2).
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OPEN ACCESSc-Jun and c-Fos promote nuclear retention and transcriptional
machinery complex formation for transcriptional activation
(Karin, 1995; Li et al., 2004; Sasaki et al., 2006). Immunofluores-
cence imaging confirmed that MEK1/2 inhibition abolished
nuclear localization of c-Fos in response to LPS and modestly
reduced nuclear translocation of NF-kB p65 (Figures S4B and
S5). This supports a role for Erk1/2-mediated promotion of
c-Fos and NF-kB transcription factor activation downstream of
TLR4.
We next examined the role of SCIMP in activation of a panel of
Erk1/2-regulated transcription factors. Scimp-silenced BMMs
(Figure 7A) showed a selective reduction in phosphorylation of8 Cell Reports 36, 109662, September 7, 2021c-Fos, in contrast to c-Jun, within the AP-1
complex (Figure 7B), consistent with Erk1/
2 phosphorylation of c-Fos. Additionally,
there was a modest but significant reduc-
tion in NF-kB p65 phosphorylation in
response to LPS after Scimp silencing, in
line with an impairment of inhibitor of NF-
kB (IkB) degradation reported previously
(Luo et al., 2017). Erk1/2 has been shown
to activate the transcription factor C/EBPb
in response to IFN-g stimulation (Hu et al.,
2001), but no such role downstream of
TLRs has been described, and loss of
SCIMP did not affect C/EBPb activation
following LPS stimulation (Figure 7B).
Immunofluorescence analysis of c-Fos
and NF-kB p65 nuclear translocation in
LPS-treated Scimp/ BMMs revealed
reduced nuclear c-Fos at 60 min post-LPS
treatment and a milder reduction in nuclearNF-kB p65 at both 15 and 60 min post-LPS compared to WT
BMMs (Figures 7CandS5).Consistently, nuclear andcytoplasmic
fractions from LPS-treated WT and Scimp/ BMM lysates
showed a marked reduction in both nuclear NF-kB p65 and
c-Fos at 60min post-LPS treatment in the absence of SCIMP (Fig-
ure 7D). Thus, these resultsmirror thoseobtained inMEK1/2 inhib-
itor-treated BMMs (Figure S4), indicating that SCIMP likely regu-
lates c-Fos and NF-kB transcription factors through Erk1/2
signaling downstream of TLR4. The locale-specific recruitment
of Erk1/2 bySCIMP thusprovides amechanism todrive transcrip-
tion factor activation for the selective transcription of pro-inflam-
matory cytokines in TLR pathways.
Figure 6. SCIMP promotes pro-inflammatory
cytokine production in response to LPS
(A) BMMs from Scimp+/+, Scimp/, and Scimp+/
mice were stimulated with 100 ng/mL LPS for 4 h,
and respective mRNA levels were analyzed by qRT-
PCR and normalized relative to Hprt. Data are
shown as mean+SEM for fold-change of Scimp+/+
(4 h) from 3 independent experiments (n = 3), and
statistical analysis was performed using one-way
ANOVA with Sidak’s multiple comparisons test
(*p < 0.05; **p < 0.01; ****p < 0.0001).
(B) BMMs from Scimp+/+ and Scimp/ mice were
stimulated with 100 ng/mL LPS for 8 h or 24 h, and
levels of secreted TNF, IL-6, IL-10, and IL-12p40
were analyzed by ELISA. Data are shown as
mean+SEM from n = 6 mice per genotype, and
statistical analysis was performed using two-way
ANOVAwith Sidak’s multiple comparisons test (*p <
0.05; ***p < 0.001; ****p < 0.0001).
(C) BMMs from wild-type mice were treated with
Scimp siRNA, control siRNA, or no siRNA and
cultured for 24 h before stimulation with 100 ng/mL
LPS for 4 h. Respective mRNA levels were analyzed
by qRT-PCR and normalized relative to Hprt. Data
(relative to no siRNA 4 h LPS treatment) are shown
as mean+SEM from 3 independent experiments
(n = 3), and statistical analysis was performed using
one-way ANOVAwith Sidak’s multiple comparisons
test (**p < 0.01; ***p < 0.001; ****p < 0.0001).
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SCIMP in macrophages and delineate a mechanism by which
SCIMP recruits and scaffolds Erk1/2 to TLR4 at the cell mem-
brane for c-Fos and NF-kB activation to selectively drive Erk1/
2-mediated pro-inflammatory responses.
DISCUSSION
The transmembrane adaptor SCIMP has previously been char-
acterized as a TLR adaptor in macrophages where it promotes
specific pro-inflammatory cytokine production downstream of
multiple TLRs (Luo et al., 2017, 2020). Mechanistically, we now
show that SCIMP recruits and scaffolds Erk1/2 at key TLR4-Cesignaling sites localized to membrane ruf-
fles and macropinosomes, in an LPS-
inducible manner. Using BMMs from
Scimp/mice, previously used to charac-
terize the role of SCIMP in dectin-1
signaling (Kralova et al., 2016), we show
that a defect in LPS-induced pro-inflam-
matory cytokine expression is consistent
with defective recruitment of Erk1/2 to
TLR4 and impaired Erk1/2-mediated nu-
clear localization of c-Fos and NF-kB for
transcriptional activation. Given the well-
established roles of Erk1/2 in inflammatory
responses downstream of TLRs, our re-
sults now address an unmet question of
how Erk1/2 is spatiotemporally recruited
for pro-inflammatory TLR signaling. Wepose SCIMP as a key transmembrane scaffold for recruiting
Erk1/2 to TLR4 to elicit a rapid, tailored pro-inflammatory
response primarily through c-Fos and NF-kB activation
(Figure S6).
In other cell-signaling pathways, Erk1/2 is generally recruited
to RTKs by scaffolds that can bindmultiple members of the clas-
sical Ras guanosine triphosphatase (GTPase)-MAPK signaling
cascade, including Raf, MEK, and Erk (McKay and Morrison,
2007); however, these scaffolds are not known to be available
in TLR settings. Ras activation can be promoted through Grb2/
SOS complex formation and post-translational modification-
dependent recruitment to specific cell membranes (Eisenberg
and Henis, 2008). Although Grb2 is a known SCIMP effector,ll Reports 36, 109662, September 7, 2021 9
Figure 7. SCIMP promotes c-Fos and NF-kB
activation in response to LPS
(A) BMMs from wild-type mice were treated with
Scimp siRNA, control siRNA, or no siRNA and
cultured for 24 h. Representative immunoblot
(upper) and quantification (lower) show SCIMP
knockdown after siRNA treatment.
(B) Representative immunoblots show levels of
phospho-c-Fos (Ser-32), phospho-c/EBPb (Thr-
235), phospho-c-Jun (Ser-63), and phospho-NF-kB
p65 (Ser-536) at 0, 15, 30, and 60 min post-LPS
stimulation (100 ng/mL) in Scimp siRNA-, control
siRNA-, or no siRNA-treated BMMs.
Data from (A) and (B) are shown as mean+SEM of
chemiluminescence relative to GAPDH loading
control from 3 independent experiments (n = 3), and
statistical analysis was performed using Student’s t
test compared to control siRNA treatment (B) at
15 min post-LPS (*p < 0.05; **p < 0.01).
(C) Representative immunofluorescence images
show c-Fos and NF-kB p65 nuclear localization
after 0, 15, and 60 min post-LPS in WT (Scimp+/+)
and Scimp/ BMMs. Scale bar: 50 mm. Data are
shown as mean+SEM fluorescence (a.u.) from n >
100 cells per condition, and statistical analysis was
performed using two-way ANOVA with Sidak’s
multiple comparisons post hoc test (****p < 0.0001).
(D) Representative immunoblots show levels of NF-
kB p65 and c-Fos in nuclear and cytoplasmic
fractions of lysates fromWT andScimp/BMMs 0,
15, and 60 min post-LPS stimulation (100 ng/mL). b
tubulin and lamin A/C were used as cytoplasmic
and nuclear markers, respectively. Quantification of
NF-kB p65 and c-Fos in nuclear fraction is shown
as mean+SEM of chemiluminescence relative to
lamin A/C from 3 independent experiments (n = 3),
and statistical analysis was performed using two-
way ANOVA with Sidak’s multiple comparisons
post hoc test (**p < 0.01; ****p < 0.0001).
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by SCIMP does not require the presence of Grb2, and we did not
detect upstream kinases, such as TPL2, Raf, or MEK in our
SCIMP pull-downs. The immune-specific scaffolding function
of SCIMP was further demonstrated by the lack of SCIMP
enrichment at sites of Erk2 membrane recruitment stimulated
by EGF, a Ras-Raf-Grb2-SOS-dependent process, indicating
that SCIMP is not implicated in EGFR-mediated Erk1/2 signaling.10 Cell Reports 36, 109662, September 7, 2021Previously, we showed that SCIMP can
regulate activation of other MAPKs,
including p38 and c-Jun N-terminal kinase
(JNK), downstream of TLR4 (Luo et al.,
2017). However, neither of these MAPKs
was present in SCIMP pull-down experi-
ments. Thus, the activation of p38 and
JNK are likely to be mediated by other
SCIMP effectors, such as the tyrosine
family kinase, Lyn (Avila et al., 2012).
SCIMP therefore appears to show selec-
tivity as a scaffold, recruiting Erk1/2, but
not other MAPKs. For Erk1/2, the selec-tivity of SCIMP as a scaffold for each of the Erk isoforms 1 and
2 remains more of an open question. Our mass spectrometry
analysis identified Erk2, but not Erk1, as a SCIMP interactor,
but subsequent SCIMP pull-downs detected both Erk isoforms.
This may reflect the lower abundance of Erk1 compared to Erk2
inmacrophage lysates (see Figure 3B), and so further studies are
needed to resolve whether SCIMP has Erk isoform selectivity.
Indeed, the redundancy of Erks1 and 2 has long been debated,
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factor in determining Erk1/2 signaling (Buscà et al., 2016).
A feature of scaffolds is their ability to modulate the duration
and amplitude of signaling (McKay and Morrison, 2007). Consis-
tent with this, loss of SCIMP reduced the strength of the Erk1/2
signal at a single 15-min peak in our experiments. SCIMP can
also promote sustained Erk1/2 activation downstream of MHC
II and dectin-1 activation in B cells and DCs (Draber et al.,
2011; Kralova et al., 2016). SCIMP is thus likely to coordinate
Erk1/2 signaling from different immune receptors. pTRAPs exist
clustered in lipid raft or TEM domains, along with multiple recep-
tors, and different pTRAPs can play overlapping or redundant
signaling roles (Curson et al., 2018). We examined the closely
related pTRAP, PAG/CBP, which also scaffolds SCIMP effectors
Lyn and Csk. Unlike SCIMP, PAG/CBP expression was not regu-
lated by LPS inmacrophages, and it did not control inflammatory
cytokine production. Thus, SCIMP appears to be acting uniquely
in this scaffolding capacity, as supported by recording defective
pro-inflammatory cytokine responses in Scimp-deficient BMMs.
The cell surface ruffles and early macropinosomes that host
TLR4 signaling in macrophages (Kagan et al., 2008; Luo et al.,
2014a) are highly dynamic membrane environments. These lo-
cales are indeed well characterized as signaling hubs, enriched
in actin polymerizing proteins, membrane phospholipids, lipid ki-
nases, signaling kinases, and small G proteins with a high rate of
turnover (Bohdanowicz et al., 2013; Swanson, 2008; Yoshida
et al., 2009). Although signaling kinases, such as the pleckstrin
homology (PH)-domain-containing Akt, are recruited by transient
accumulation of PI(3,4,5)P3 on early macropinosomes (Wall
et al., 2019), Erk1/2 has no such membrane-targeting motif.
This further highlights the requirement for a membrane-localized
protein scaffold for Erk1/2 in TLR pathways. As a palmitoylated
transmembrane protein, SCIMP is strategically positioned to re-
cruit signaling kinases directly to the receptor complexes in lipid
raft signaling domains. With the advent of high-resolution LLSM,
it is possible to resolve distinct and highly dynamic membrane
compartments and protein recruitment. Our ability to capture
TLR4-induced enrichment of Erk1/2 with SCIMP at highly spe-
cific and dynamic sites on membranes graphically illustrates
both the recruitment of a subset of the cytosolic Erk1/2 to ruffles
and macropinosomes and the need for SCIMP as a scaffold at
these sites. Thus, this spatiotemporal recruitment of Erk1/2
matches the compartmentalization of the SCIMP and Erk1/2-
mediated signaling required to specifically generate pro-inflam-
matory responses.
In addition to IL-6 and IL-12p40, these data now show that
SCIMP promotes the production of pro-inflammatory cytokines
pro-IL-1b and TNF downstream of TLR4 stimulation in primary
macrophages. Following TLR-induced expression, IL-1b is
released by innate immune cells in its mature form following acti-
vation of the inflammasome multimeric protein complex, which
leads to pro-IL-1b cleavage, induction of pyroptotic inflamma-
tory cell death, and secretion of mature IL-1b (Chan and
Schroder, 2020). Recently, a key role for SCIMP in alternative in-
flammasome activation has emerged. In addition to scaffolding
Lyn for TLR and B cell receptor signaling (Draber et al., 2011;
Luo et al., 2017), SCIMP additionally recruits Syk kinase for cas-
pase-8-dependent NLRP3 inflammasome assembly and matureIL-1b secretion downstream of TLR2/4 (Zewinger et al., 2020).
Complementary to these findings, we show that SCIMP pro-
motes the Erk1/2-mediated expression of pro-IL-1b down-
stream of TLR4, thereby underlining the importance of the
SCIMP as a crucial multi-level regulator of IL-1b production in
macrophages. Distinct to its role in promotion of TLR-induced
pro-IL-1b expression, Erk1/2 signaling also plays an important
role in NLRP3 inflammasome priming (D’Espessailles et al.,
2018; Ghonime et al., 2014). Therefore, it remains to be seen
whether SCIMP is also an Erk1/2 scaffold in inflammasome acti-
vation pathways.
In TLR pathways, the kinase TPL2 acts downstream of multi-
ple TLR adaptors, including MyD88/MAL and TRIF/TRAM for
activation of MEK/Erk and c-Fos for inflammatory output,
including control of TRIF-dependent IFN-b and IL-10 production
(Banerjee et al., 2006; Kaiser et al., 2009). In line with this, we
show that activity of the TPL2 downstream kinase MEK1/2 is
essential for Erk1/2 phosphorylation and c-Fos activation.
MEK1/2 inhibition abolishes both MyD88-dependent pro-inflam-
matory and TRIF-dependent type I interferon genes downstream
of TLR4. However, SCIMP does not control Erk1/2-dependent
IL-10 and IFN-b production. Thus, our data suggest that a subset
of Erk1/2 scaffolded by SCIMP selectively drives only the pro-in-
flammatory signaling branch downstream of TLR4. Interestingly,
the recruitment of Erk1/2 by SCIMP is dependent on surface
TLR4 adaptor Mal, but not on endosomal TLR4 adaptors TRIF
or TRAM (Figure 3E). It may be that endosomal TLR adaptors uti-
lize an alternative signaling adaptor for Erk1/2 recruitment and
activation downstream of TLR4 for type I interferon production.
Therefore, our data are consistent with SCIMP acting at the sur-
face for TLR4 signaling, highlighting an interesting segregation of
Erk1/2 activation between MyD88-dependent surface and TRIF-
dependent endosomal TLR4 signaling.
The promotion of c-Fos and NF-kB activation by SCIMP in
response to LPS is concurrent with the role of these potent tran-
scription factors in inflammatory cytokine production. The spe-
cific regulation of Erk1/2-mediated c-Fos activation within the
AP-1 complex, but not c-Jun, which is primarily regulated by
the MAPK JNK (Ip and Davis, 1998), points to the specificity of
the SCIMP inflammatory response. Although the AP-1 complex
is a key pro-inflammatory modulator (Shaulian and Karin,
2002), macrophages from c-Fos-deficient mice conversely
display increased production of TNF, IL-6, and IL-12p40 in
response to LPS, which can be attributed to upregulated NF-
kB expression (Ray et al., 2006). NF-kB and AP-1 can be simul-
taneously activated by the same stimuli and show synergistic
cross-talk for enhanced gene expression (Stein et al., 1993),
and NF-kB regulates c-Fos expression and AP-1 activation
through Elk-1 and MAPK signaling (Fujioka et al., 2004). In addi-
tion to c-Fos, Erk1/2 can activate NF-kB through IkB kinase (IKK)
(Chen and Lin, 2001; Eliopoulos et al., 2003; Kawai and Akira,
2007). Hence, interplay between SCIMP-mediated c-Fos and
NF-kB activation through Erk1/2 may provide a further means
to tailor specific pro-inflammatory output downstream of TLR4.
Finally, TLR signaling dysfunction is associated with the path-
ogenesis of autoimmune diseases (Barrat et al., 2005; Broen
et al., 2012), many of which display MAPK/Erk1/2 dysregulation
(Arthur and Ley, 2013; Gorelik and Richardson, 2010; ThalhamerCell Reports 36, 109662, September 7, 2021 11
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OPEN ACCESSet al., 2008) and perturbed levels of pro-inflammatory cytokines
(Hirano et al., 1988; Linker-Israeli et al., 1991; Liu et al., 1999;
Turner et al., 2014). SCIMP is genetically linked to a range of in-
flammatory and autoimmune diseases, such as systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA) (Dozmorov
et al., 2014), as well as Alzheimer’s disease (AD) (Jansen et al.,
2019; Lambert et al., 2013; Liu et al., 2017; Luo et al., 2019; Mor-
eno-Grau et al., 2019) and its inherent innate immune dysfunc-
tion (Heneka et al., 2015a, 2015b). SCIMP regulation of dis-
ease-associated pro-inflammatory cytokines through the pro-
inflammatory arm of Erk1/2 signaling may therefore provide an
axis amenable to therapeutic intervention in inflammation-
related diseases.
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Antibodies
phospho-c-Fos (Ser-32), clone D82C12 Cell Signaling Technology Cat#5348; RRID: AB_10557109
phospho-C/EBPb (Thr-235) Cell Signaling Technology Cat#3084; RRID: AB_2260359
phospho-NF-kB p65 (Ser-536), clone 93H1 Cell Signaling Technology Cat#3033; RRID: AB_331284
phospho-c-Jun (Ser-63), clone E6I7P Cell Signaling Technology Cat#91952
c-Fos, clone 9F6 Cell Signaling Technology Cat#2250; RRID: AB_2247211
NF-kB p65, clone D14E12 Cell Signaling Technology Cat#8242; RRID: AB_10859369
GAPDH, clone 14C10 Cell Signaling Technology Cat#2118; RRID: AB_561053
phospho-Akt (Ser-473), clone D9E Cell Signaling Technology Cat#4060; RRID: AB_2315049
Grb2 Cell Signaling Technology Cat#3972; RRID: AB_10693935
Csk, clone C74C1 Cell Signaling Technology Cat#4980; RRID: AB_2276592
SLP65/BLNK, clone D8R3G Cell Signaling Technology Cat#12168; RRID: AB_2756401
Lyn, clone C13F9 Cell Signaling Technology Cat#2796; RRID: AB_2138391
phospho-Src Family (Tyr-416), clone D49G4 Cell Signaling Technology Cat#6943; RRID: AB_10013641
Erk1/2, clone 137F5 Cell Signaling Technology Cat#4695; RRID: AB_390779
phospho-Erk1/2, clone D13.14.4E Cell Signaling Technology Cat#4370; RRID: AB_2315112
Lamin A/C, clone 4C11 Cell Signaling Technology Cat#4777; RRID: AB_10545756
b-tubulin, clone 9F3 Cell Signaling Technology Cat#2128; RRID: AB_823664
TLR4, clone 76B357.1 Abcam ab22048; RRID: AB_446735
Erk1/2, clone EPR17526 Abcam ab184699; RRID: AB_2802136
V5 antibody, clone SV5-PK1 Bio-Rad/AbD Serotec MCA1360; RRID: AB_322378
SCIMP Luo et al., 2017 N/A
Alexa Fluor 488 Molecular Probes A21206; RRID: AB_2535792
anti-Mouse IgG (H+L) HRP Thermo Fisher Scientific G-21040; RRID: AB_2536527
anti-Rabbit IgG (H+L) HRP Thermo Fisher Scientific G-21234; RRID: AB_2536530
Mouse IL-6, clone MP5-20F3 BD OptEIA Cat#554400; RRID: AB_398549
Mouse IL-6 Biotin, clone MP5-32C11 BD OptEIA Cat#554402; RRID: AB_395368
Mouse IL-12p40, clone C15.6 BD OptEIA Cat#551219; RRID: AB_394097
Mouse IL-12p40 Biotin, clone C17.8 BD OptEIA Cat#554476; RRID: AB_395419
Bacterial and virus strains
E.Coli BL21-CodonPlus (DE3)-RP Agilent Technologies Cat#230255
Chemicals, peptides, and recombinant proteins
40,6-Diamidino-20-phenylindole dihydrochloride (DAPI) Sigma-Aldrich Cat#32670
Rhodamine Phalloidin Molecular Probes R415
Alexa Fluor 647 Phalloidin Molecular Probes A22287
JF 549 HaloTag L.Lavis (Janelia, Ashburn, VA) N/A
LPS from Salmonella enterica serotype minnesota Re 595 Sigma-Aldrich L9764
Human EGF Recombinant Protein Thermo Fisher Scientific PHG0311
U0126 Sigma-Aldrich U120
Recombinant human M-CSF/CSF-1 ImmunoTools GmbH Cat#11343118
Lipofectamine 2000 Thermo Fisher Scientific Cat#11668019
488-Dextran 70,000 MW Thermo Fisher Scientific D7173
Critical commercial assays
Mouse TNF ELISA kit BD OptEIA Cat#558534
Mouse IL-10 AlphaLISA kit Perkin Elmer AL502
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Experimental models: Cell lines
Mal/, Trif/,Trif/ /Tram/ iBMMs Dr Ashley Mansell, Hudson Institute




CRISPR/Cas9-mediated SCIMP knockout (KO) RAW264.7 Luo et al., 2017 N/A
CRISPR/Cas9-mediated SCIMP knockout (KO) RAW264.7
stably expressing SCIMP-V5
Luo et al., 2017 N/A
Experimental models: Organisms/strains
C57BL/6N-Scimptm1a(KOMP)Wtsi/Mmucd Mutant Mouse Resource and Research
Center
RRID: MMRRC_049566-UCD
C57BL6/J-Cbp/ Animal Resources Centre, Murdoch,
WA, Australia
N/A





















siRNA: mScimp #1: sense sequence: 50-AGACAAC
CCUCAGCUUGGUACUCAU-30
Luo et al., 2017 N/A
siRNA: mScimp #1: antisense sequence: 50-AUGAGUAC
CAAGCUGAGGGUUGUCU-30
Luo et al., 2017 N/A
siRNA: control (mHdac1 #1): sense sequence:
50-GAACUACCCACUGCGAGACGGCAUU-30
Luo et al., 2017 N/A
siRNA: control (mHdac1 #1): antisense sequence:
50-AAUGCCGUCUCGCAGUGGGUAGUUC-30
Luo et al., 2017 N/A




pGEX-6P-1-GST-SCIMP-T1 Luo et al., 2017 N/A
pGEX-6P-1-GST-SCIMP-T1-Y58F Luo et al., 2017 N/A
pGEX-6P-1-GST-SCIMP-T1-Y96F Luo et al., 2017 N/A
pGEX-6P-1-GST-SCIMP-T1-Y120F Luo et al., 2017 N/A
pGEX-6P-1-GST-SCIMP-T2 Luo et al., 2017 N/A
pGEX-6P-1-GST-TLR4-TIR Luo et al., 2017 N/A
pEF6-TSP-Halo-SCIMP-V5 This paper N/A
pEF6-GFP-Erk2 This paper N/A
Software and algorithms
ProteinPilot v6 AB Sciex https://sciex.com/products/software/
proteinpilot-software
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GraphPad Prism 9 GraphPad http://www.graphpad.com/scientific-
software/prism
Zeiss Zen 2 Zeiss https://www.zeiss.com/microscopy/int/
products/microscope-software/zen.html
Zeiss Zen Black Zeiss https://www.zeiss.com/microscopy/int/
products/microscope-software/zen.html
SlideBook 6 3i https://www.intelligent-imaging.com/
slidebook
Image Lab Bio-Rad https://commerce.bio-rad.com/en-au/
product/image-lab-software
ImageJ Schindelin et al., 2012 https://imagej.net/software/fiji






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lin
Luo (l.luo@imb.uq.edu.au).
Materials availability
All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement and
reasonable compensation by the requestor for their processing and shipping.
Data and code availability
All data reported in this paper will be shared by the Lead Contact upon request.
This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is avail-
able from the Lead Contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Male and femalemice of 8-12weeks of agewere used for this study.Micewere housedwith rodent chowandwater ad libitum in groups
of up to five animals per cage in a specific pathogen-free (SPF) facility with a 12-hour light/dark cycle. For wild-type primary macro-
phages, C57BL/6J mice were obtained from an in-house breeding colony. Scimp/ mice (strain C57BL/6N-Scimptm1a(KOMP)Wtsi/
Mmucd, RRID: MMRRC_049566-UCD) were obtained from the Mutant Mouse Resource and Research Center (MMRRC) at
University of California atDavis, anNIH-funded strain repository, andwasdonated to theMMRRCbyTheKOMPRepository, University
of California, Davis; Originating from Ramiro Ramirez-Solis, CSD. Scimp+/+ and Scimp+/ littermates were used as controls as indi-
cated. Pag/Cbp/ mice (C57BL6/J-Cbp/) were obtained from the Animal Resources Centre (Murdoch, WA, Australia).
Cell lines
Bone marrow cells were collected from femurs and tibias of 8-12 week old mice and ex vivo differentiated in RPMI 1640 medium
supplemented with 2 mM L-glutamine (Invitrogen, VIC, Australia), 10% heat-inactivated fetal bovine serum, 50 U/ml penicillin and
50 mg/ml streptomycin (Thermo Fisher Scientific, Australia) and 100 ng/ml purified recombinant macrophage colony stimulating fac-
tor–1 (CSF-1) (11343118; ImmunoTools GmbH) over 7 days at 37C in humidified 5% CO2 to obtain BMMs as previously described
(Luo et al., 2017). ImmortalizedMal/, Trif-/- and Trif//Tram/BMMs (generously provided by Dr AshleyMansell, Hudson Institute
ofMedical Research,Melbourne, Australia) were cultured in the samemedia as BMMswithout the addition of CSF-1. RAW264.7 cells
(ATCC) were maintained in RPMI 1640 medium supplemented with 2 mM L-glutamine (Invitrogen, VIC, Australia) and 10% heat-in-
activated fetal bovine serum. Generation of CRISPR/Cas9-mediated SCIMP knockout (KO) RAW264.7 cells and reconstituted
SCIMP-V5 stable cell line has previously been described (Luo et al., 2017). All cells were cultured at 37C in humidified 5% CO2.
Bacterial Strains
DNA constructs were transformed into chemically competent E.Coli BL21-CodonPlus (genotype: E. coli B F– ompT hsdS(rB
– mB
–)




All studies involving animals and use of primarymouse cells were reviewed and approved by the appropriate animal ethics committee
at University of Queensland (approval number: IMB/351/19).
METHOD DETAILS
Generation of DNA constructs and protein expression
GST-SCIMP T1 (amino acids 29–150) andGST-SCIMP-T2 (amino acids 93–150) were produced by PCRamplification from full-length
mouse SCIMP cDNA and subcloned into the pGEX-6P-1 vector (Luo et al., 2017). GST-SCIMP-T1 (Y58F, Y96F and Y120F) were
generated using a QuikChange site-directed mutagenesis kit (Stratagene). GST-TLR4-TIR (amino acids 670–835) was produced
from pET28a-TIR4-TIR (Luo et al., 2017) and subcloned into pGEX6P-1. All constructs were confirmed by DNA sequencing at the
Australian Genome Research Facility (AGRF, Brisbane, Australia). GST fusion proteins were expressed in E. coli and purified using
glutathione-Sepharose beads (Amersham Biosciences). For design of Halo-tagged expressible SCIMP construct (pEF6-TSP-Halo-
SCIMP-V5), a gBlocks gene fragment containing the transmembrane signal peptide (TSP) and 2xMyc-tag was designed and ordered
from IDT Technologies (Singapore) (Key resources table). The gene fragment was inserted into an empty pEF6-V5-HIS-TOPO back-
bone (Catalog number: K961020, Thermo Fisher Scientific, Australia) via Gibson Assembly as per manufacturer’s instruction
(NEBiolabs, Australia). HaloTag was digested out of a pEF1a-Halo-Rab13 plasmid (Condon et al., 2018) using restriction digest
(NheI and AsiSI) and theHaloTag fragment was ligated into the newly formed pEF6 backbonewith the gBlocks gene fragment. BamHI
and PmeI were inserted into pef6-TSP-Halo vector by using PCR and gblock_Halo_SCIMP primer sets (Key resources table). The
SCIMP gene was digested out of the pEF6/V5-His TOPO TA-SCIMP construct (Luo et al., 2020) by using BamHI and PmeI restriction
enzymes. The SCIMP fragment was then purified and inserted into the pEF6 backbone now containing the TSP, Myc-tag, BamHI/
PmeI restriction sites and HaloTag via Gibson Assembly. The final construct as well as intermediate stages were sequenced for ac-
curacy. The mouse Erk2 full-length construct was amplified by PCR from cDNA using two primers (Key resources table), and then
cloned into the pEF6-GFP-N1 vector and confirmed by DNA sequencing.
siRNA-mediated gene silencing and DNA transfection
siRNA knockdown of SCIMP in BMMswas performed at day 6 using electroporation as previously described (Luo et al., 2017, 2020).
Briefly, cells were resuspended in complete media at a concentration of 53 106 cells/350 ml with addition of 10 ml 1 M HEPES (tissue
culture grade) per ml of cells. 350 ml of the cell suspension was transferred to 0.4 cm electroporation cuvettes andmixed with siRNAs
against SCIMP or HDAC1 (control gene) to a final concentration of 0.5 mM or tissue culture grade water (no siRNA control) in a final
volume of 400 ml. Cells were electroporated at 240 V, 1,000 mF andNU andwashed twice before plating at the appropriate cell num-
ber. Cells were treated with indicated stimuli at 24 h post-electroporation. siRNA sequences are listed in the Key resources table.
Transient transfection of Halo-SCIMP and GFP-Erk2 into RAW264.7 cells was performed using Lipofectamine 2000 (Thermo Fisher
Scientific, Australia) according to the manufacturer’s instructions.
Immunoblotting
BMMs were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris–HCl, 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate) with cOmplete Mini protease and PhosSTOP phosphatase inhibitors (Sigma-Aldrich
Castle Hill, NSW, Australia). For nuclear and cytoplasmic fractionation, BMMswere lysed using an NE-PERNuclear and Cytoplasmic
Extraction Kit (78833, Thermo Fisher Scientific, Australia) following the manufacturer’s instructions. Protein was quantified by bicin-
choninic acid assay (Thermo Fisher Scientific, Australia) and boiled in sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) sample buffer for 5 min at 95C. Following separation on 10%SDS-PAGE, proteins were transferred to a polyvinylidene
difluoride membrane (Bio-strategy, Tingalpa QLD, Australia), blocked with 5%BSA (Sigma-Aldrich Castle Hill, NSW, Australia) or 5%
skim milk in tris-buffered saline (TBS)/0.1% Tween-20 and incubated with primary antibodies diluted 1:1000 overnight at 4C. After
washing,membraneswere incubatedwith secondary antibody diluted 1:10,000 for 1 h and chemiluminescencewas developed using
ECL detection reagent (Thermo Fisher Scientific, Australia) and imaged using a ChemiDoc and Image Lab Software (Bio-Rad
Laboratories, Hercules, CA, USA). Densitometry analysis was performed using ImageJ Fiji version 2.1.0/1.53c (National Institutes
of Health, MD, USA).
Affinity pull down and co-immunoprecipitation
RAW267.4 cells, iBMMs or BMMs from SCIMP mice were stimulated with 100 ng/ml LPS for 30 min as indicated and lysed in lysis
buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 5% glycerol, cOmplete Mini protease and PhosSTOP phosphatase inhibitors
(Sigma-Aldrich Castle Hill, NSW, Australia)). Lysates were incubated with GST, GST-SCIMP-T1/T2/Y58F/Y96F/Y120F and GST-
TLR4-TIR Sepharose beads in MicroSpin columns (GE Healthcare) for 16 h at 4C. Beads were washed with ice-cold wash buffer
(20 mM Tris, 150 mM NaCl, 1% NP-40, pH 7.4) and bound protein was eluted by boiling in 2 3 SDS-PAGE sample buffer for
5 min at 95C. For immunoprecipitation experiments, control or 30 min LPS-treated RAW264.7 cells stably expressing SCIMP-V5
or Scimp+/+ or Scimp/ BMMs were lysed in lysis buffer as above and cleared lysates were incubated with anti-V5 or anti-Erk1/2
antibody-bound protein G agarose beads (Thermo Fisher Scientific, Australia) for 16 h at 4C. Beads were washed with lysis buffere4 Cell Reports 36, 109662, September 7, 2021
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OPEN ACCESSand bound protein were eluted in 2x SDS-PAGE sample buffer. For pull down and immunoprecipitation experiments proteins were
separated by 10% SDS-PAGE and analyzed by immunoblotting.
Mass spectrometry
LC MS/MS analysis of binding partners from a GST-SCIMP-T1 pull down in RAW263.7 cells was performed on a Shimadzu Prom-
inence Nano HPLC (Japan) coupled to a Triple TOF 5600 mass spectrometer (ABSCIEX, Canada) equipped with a nano electrospray
ion source (IMB Mass Spectrometry Facility, The University of Queensland) (Luo et al., 2014b, 2017). Peptide extracts (6 ml) were in-
jected onto a 50 mm 3 300 mm C18 trap column (Agilent Technologies, Australia) at 30 ml min1 and desalted for 5 min using 0.1%
formic acid at 30 ml min1. The trap columnwas then placed in-line with the analytical nano high-performance liquid chromatography
column and a 150 mm3 75 mm300SBC18 column (Agilent Technologies, Australia) for mass spectrometry analysis. Linear gradients
of 1%–40% solvent B over 35 min at a flow rate of 300 nl min1, followed by a gradient from 40 to 80% solvent B in 5 min were used
for peptide elution. Solvent Bwas held at 80% for 5 min for washing the column and returned to 1% solvent B for equilibration, before
injection of the next sample. Solvent A consisted of 0.1% formic acid and solvent B contained 90/10 acetonitrile/0.1% formic acid.
The ion spray voltagewas set to 2,400 V, declustering potential (DP) 100 V, curtain gas flow 25, nebulizer gas 1 (GS1) 12 and interface
heater at 150 C. The mass spectrometer acquired 500 ms full-scan time-of-flight mass spectrometry (TOF-MS) data followed by 20
by 50 ms full-scan product ion data in an information-dependent acquisition mode. Full-scan TOF-MS data were acquired over the
mass range 350–1,400 and for product ion ms/ms 80–1,400. Ions observed in the TOF-MS scan exceeding a threshold of 100 counts
and a charge state of +2 to +5 were set to trigger the acquisition of product ion, ms/ms spectra of the resultant 20 most intense ions.
The data were acquired and processed using Analyst TF 1.6.1 software (ABSCIEX, Canada). Proteins were identified by database
searching using ProteinPilot v6 (ABSCIEX, Canada) against the UniProt_Sprot database. Search parameters were defined as a thor-
ough search using trypsin digestion and all entries in the database. Proteins were considered identified if there was at least one pep-
tide identified with 99% confidence (mass spectrometry score at least 2).
Gene expression and cytokine analysis
Total RNAwas extracted from cells and DNaseI-treated using an RNeasyMini Kit following themanufacturer’s instructions (QIAGEN,
VIC, Australia) and RNA concentrations were determined using a NanoDrop ND-1000 (Thermo Fisher Scientific, Australia). 1 mg RNA
was reverse transcribed into cDNA using oligoDT primers and SuperScript III (Invitrogen, VIC, Australia). Gene expression was quan-
tified using SYBR Green (Applied Biosystems, Massachusetts, USA) RT-qPCR on an Applied Biosystems ViiA7 Real Time PCR sys-
tem (Life Technologies/Thermo Fisher Scientific, Australia) using gene-specific primers (Table S1), with expression determined using
the DCt method and normalized to Hprt.
For quantification of cytokine secretion, BMMs (1x106 cells/ml) were treated with 100 ng/ml LPS for 8 h or 24 h and supernatants
were collected and analyzed for levels of secreted cytokines using a BD OptEIA ELISA kit (mouse TNF 558534) or paired antibodies
(IL-6 554400/554402 and IL-12p40 551219/554476) (BD Biosciences, Australia) or AlphaLISA kit (mouse IL-10, AL502, Perkin Elmer,
VIC, Australia) following the manufacturer’s instructions. Absorbance was measured at 450 nm (BD OptEIA) or with excitation and
emission at 680 nm and 615 nm respectively (AlphaLISA) using a Tecan Infinite M1000 Pro microplate reader (Thermo Fisher Scien-
tific, Australia) and analyzed using GraphPad Prism 9 (San Diego, CA, USA).
Immunofluorescence & fixed cell imaging
BMMs were grown on #1.5 coverslips and fixed in 4% paraformaldehyde (PFA) and permeabilized with 0.1% Triton X-100 for 5 min
before immunolabelling with primary antibodies diluted 1:500 in 0.5% bovine serum albumin/PBS for 1 h at RT. After washing, cells
were incubated in secondary antibody diluted 1:400 in 0.5% bovine serum albumin/PBS with Rhodamine Phalloidin (R415) and 40,6-
Diamidino-20-phenylindole dihydrochloride (DAPI) for 1 h at RT. Coverslips were mounted on microscope slides using ProLong Dia-
mond mountant (Thermo Fisher Scientific, Australia) and sealed with nail polish. 5 phase shift images were acquired on an Axio
Imager M2 with Apotome.2 fitted with a Plan Neofluar 40x NA 1.3 oil objective and illuminated with a CoolLED light source and
captured in Zeiss Zen 2 software with a Zeiss Axiocam 506 camera (Zeiss, Oberkochen, Germany).
For RAW264.7 cells transfected with Halo-SCIMP andGFP-Erk2, cells were grown on #1.5 coverslips and incubated with 10 nM JF
549 HaloTag ligand for 30 min at 37C, washed with PBS and fixed in 4% paraformaldehyde (PFA) and permeabilized with 0.1%
Triton X-100 before being incubated with phalloidin-647 diluted in 0.5% BSA/PBS for 45 min and mounted on microscope slides us-
ing ProLong Diamond mountant (Thermo Fisher Scientific, Australia) and sealed with nail polish. Cells were imaged with a Zeiss LSM
880Confocal using Fast Airyscanmode on an Axiovert 200 InvertedMicroscopewith a Plan Apochromat 63x NA 1.4 oil objective and
using Zeiss Zen Black software (Zeiss, Oberkochen, Germany).
Live cell imaging of dextran uptake
RAW264.7 cells stably expressing SCIMP-V5 were grown on 35 mmMatTek glass bottom dishes. Cells were incubated with 10 nM
JF 549 HaloTag ligand for 30 min at 37C before incubation with 488-Dextran (70,000 MW) (Thermo Fisher Scientific, Australia) and
100 ng/ml LPS for 30 min prior to imaging. Time series images were captured using a Zeiss LSM 880 Confocal on an Axiovert 200
Inverted Microscope with a Plan Apochromat 63x NA 1.4 oil objective and using Zeiss Zen Black software (Zeiss, Oberkochen,
Germany).Cell Reports 36, 109662, September 7, 2021 e5
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For LLSM, CRISPR/Cas9-mediated SCIMP KO RAW264.7 cells were transfected with Halo-SCIMP and GFP-Erk2 and plated at
0.23 106 cells/ml on 5 mm round #1 coverslips. Halo-549 ligand was added to the cells 30 min prior to imaging. For LLSM imaging,
cells were incubated CO2-free in L-15 medium (supplied with 10% FCS 2 mM L-glutamine and 10 mg/ml Pen/Strep) and stimulated
with 100 ng/ml LPS (Sigma-Aldrich). Image volumes of at least 106x53x75 mm (XYZ) were imaged continuously for 20 min at 3.2 s
intervals, consisting of at least 151 planes at 10 ms exposures/channel sequentially. Imaging was carried out using a 3i lattice
light-sheet V2 microscope, samples were illuminated with a Coherent Sapphire 488 nm diode laser at and MPB Communications
560 nm diode laser both at 1%–2% AOTF transmittance through an excitation objective (Special Optics 28.63 0.7 NA 3.74-mmwa-
ter dipping lens) at an angle of 31.8 degrees. Individual sheets were generated using 3i Slidebook software (488 nm 52 beams,
0.960 mm spacing, 560 nm 45 beams, 1.102 mm spacing both with a cropping factor of 0.150 mmand spacing factor of 0.970) through
a 0.550/0.493 NA annular mask. Fluorescence signal was detected with a Nikon 25x 1.1 NA CFI Apo LWD objective and 2.5X tube
lens (62.5x total system magnification) using 2x Hamamatsu Orca Flash 4.0 V2 sCMOS cameras running SlideBook 6 software (3i,
Colorado, USA). Post processing of LLSM data includes GPU-accelerated deskewing and 10-40 cycles of deconvolution based on
the Richard-Lucy algorithm (Microvolution, California, USA).
QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis
All image analysis was carried out in ImageJ (Fiji version 2.1.0/1.53c)(Schindelin et al., 2012). For nuclear translocation analysis in
Figures 7C and S4B, c-Fos and NF-kB fluorescent signal intensity was measured in nuclear regions segmented from DAPI signal.
For LLSM images in Figures 4B and 4C, co-localization between image channels was calculated from maximum and sum intensity
projections using the AND function in image calculator and visualized using FireLUT. 4D renders in Video S4were created using Arivis
Vision4D 3.3 software.
Statistics
All datasets subjected to statistical analysis were compiled from at least 3 independent experiments as indicated. All data are pre-
sented as arithmetic mean ± SEM. Student’s t test was used for direct comparison of a single experimental variable. For datasets
containing multiple comparisons between three or more groups, a one-way or two-way analysis of variance (ANOVA) was performed
with post-test as indicated. In all statistical analyses, a P value < 0.05 was considered statistically significant and descriptions of in-
dividual P values calculated for each experimental comparison are stated in the respective figure legends. Statistics were calculated
using GraphPad Prism 9 (San Diego, CA, USA).e6 Cell Reports 36, 109662, September 7, 2021
